53216 Federal Register / Vol. 79, No. 173 / Monday, September 8, 2014 / Notices 

equipment manufacturers, separation 

system designers, and end users. 

Patricia A. Brink, 

Director of Civil Enforcement, Antitrust 

Division. 

[FR Doc. 2014–21286 Filed 9–5–14; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–393] 

Established Aggregate Production 

Quotas for Schedule I and II Controlled 

Substances and Assessment of 

Annual Needs for the List I Chemicals 

Ephedrine, Pseudoephedrine, and 

Phenylpropanolamine for 2015 

AGENCY: Drug Enforcement 

Administration (DEA), Department of 

Justice (DOJ). 

ACTION: Notice. 

SUMMARY: This notice establishes the 

initial 2015 aggregate production quotas 

for controlled substances in schedules I 

and II of the Controlled Substances Act 

(CSA) and the assessment of annual 

needs for the list I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine. 

DATES: Effective date: Effective 

September 8, 2014. 

FOR FURTHER INFORMATION CONTACT: 

Imelda Paredes, Executive Assistant, 

Office of Diversion Control, Drug 

Enforcement Administration, 8701 

Morrissette Drive, Springfield, VA 

22152, Telephone: (202) 598–6812. 

SUPPLEMENTARY INFORMATION: 

Legal Authority 

The Drug Enforcement 

Administration (DEA) implements and 

enforces titles II and III of the 

Comprehensive Drug Abuse Prevention 

and Control Act of 1970, as amended. 

Titles II and III are referred to as the 

‘‘Controlled Substances Act’’ and the 

‘‘Controlled Substances Import and 

Export Act,’’ respectively, and are 

collectively referred to as the 

‘‘Controlled Substances Act’’ or the 

‘‘CSA’’ for the purpose of this action. 21 

U.S.C. 801–971. The DEA publishes the 

implementing regulations for these 

statutes in title 21 of the Code of Federal 

Regulations (CFR), parts 1300 to 1321. 

The CSA and its implementing 

regulations are designed to prevent, 

detect, and eliminate the diversion of 

controlled substances and listed 

chemicals into the illicit market while 

providing for the legitimate medical, 

scientific, research, and industrial needs 

of the United States. Controlled 

substances have the potential for abuse 

and dependence and are controlled to 

protect the public health and safety. 

Section 306 of the Controlled 

Substances Act (CSA) (21 U.S.C. 826) 

requires the Attorney General to 

establish aggregate production quotas 

for each basic class of controlled 

substance listed in schedules I and II 

and for ephedrine, pseudoephedrine, 

and phenylpropanolamine. This 

responsibility has been delegated to the 

Administrator of the DEA through 28 

CFR 0.100(b). The Administrator, in 

turn, has redelegated this function to the 

Deputy Administrator, pursuant to 28 

CFR pt. 0 subpt. R, App. 

Background 

The 2015 aggregate production quotas 

and assessment of annual needs 

represent those quantities of schedule I 

and II controlled substances and the list 

I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine to be 

manufactured in the United States in 

2015 to provide for the estimated 

medical, scientific, research, and 

industrial needs of the United States, 

lawful export requirements, and the 

establishment and maintenance of 

reserve stocks. These quotas include 

imports of ephedrine, pseudoephedrine, 

and phenylpropanolamine but do not 

include imports of controlled 

substances for use in industrial 

processes. 

On July 2, 2014, a notice titled, 

‘‘Proposed Aggregate Production Quotas 

for Schedule I and II Controlled 

Substances and Proposed Assessment of 

Annual Needs for the List I Chemicals 

Ephedrine, Pseudoephedrine, and 

Phenylpropanolamine for 2015’’ was 

published in the Federal Register. 79 FR 

37772. This notice proposed the 2015 

aggregate production quotas for each 

basic class of controlled substance listed 

in schedules I and II and the 2015 

assessment of annual needs for the list 

I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine. All interested 

persons were invited to comment on or 

object to the proposed aggregate 

production quotas and the proposed 

assessment of annual needs on or before 

August 1, 2014. 

Comments Received 

Five comments were received from 

DEA-registered manufacturers within 

the published comment period, offering 

comments on a total of 32 schedule I 

and II controlled substances. None of 

the respondents commented on the list 

I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine. Commenters 

stated that the proposed aggregate 

production quotas for 1-(1,3- 

Benzodioxol-5-yl)-2-(methylamino) 

butan-1-one (butylone), 1-(1,3- 

Benzodioxol-5-yl)-2-(methylamino) 

pentan-1-one (pentylone), 2-(4-Bromo2,5-dimethoxyphenyl)-N-(2- 

methoxybenzyl)ethanamine (25BNBOMe), 2-(4-Chloro-2,5- 

dimethoxyphenyl)-N-(2- 

methoxybenzyl)ethanamine (25CNBOMe), 2-(4-Iodo-2,5- 

dimethoxyphenyl)-N-(2- 

methoxybenzyl)ethanamine (25INBOMe), 2-(Methylamino)-1- 

phenylpentan-1-one (pentedrone), 3- 

Fluoro-N-methylcathinone (3-FMC), 4- 

Fluoro-N-methylcathinone (4-FMC), 4- 

Anilino-N-phenethyl-4-piperidine 

(ANPP), 4-Methyl-N-ethylcathinone (4- 

MEC), 4-Methyl-apyrrolidinopropiophenone (4-MePPP), 

alpha-Pyrrolidinobutiophenone (aPBP), alpha-Pyrrolidinopentiophenone 

(a-PVP), amphetamine (for sale), 

codeine (for sale), dihydrocodeine, 

diphenoxylate, fentanyl, hydrocodone 

(for sale), hydromorphone, levorphanol, 

marihuana, morphine (for conversion), 

N-(1-Amino-3,3-dimethyl-1-oxobutan-2- 

yl)-1-pentyl-1H-indazole-3-carboxamide 

(ADB-PINACA), N-(1-Amino-3-methyl1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1Hindazole-3-carboxamide (ABFUBINACA), naphthylpyrovalerone 

(naphyrone), oripavine, oxycodone (for 

conversion), oxymorphone (for 

conversion), oxymorphone (for sale), 

Quinolin-8-yl 1-(5-fluoropentyl)-1Hindole-3-carboxylate (5-Flouro-PB-22), 

and Quinolin-8-yl 1-pentyl-1H-indole-3- 

carboxylate (PB-22) were insufficient to 

provide for the estimated medical, 

scientific, research, and industrial needs 

of the United States, export 

requirements, and the establishment 

and maintenance of reserve stocks. 

Determination of 2015 Aggregate 

Production Quotas and Assessment of 

Annual Needs 

In determining the 2015 aggregate 

production quotas and assessment of 

annual needs, the DEA has taken into 

consideration the above comments 

along with the factors set forth at 21 

CFR 1303.11 and 21 CFR 1315.11, in 

accordance with 21 U.S.C. 826 (a), and 

other relevant factors, including the 

consideration of 2014 manufacturing 

quotas, current 2014 sales and 

inventories, 2015 export requirements, 

industrial use, additional applications 

for quotas, as well as information on 

research and product development 

requirements. Based on this 

information, the DEA has determined 


rmajette on DSK2TPTVN1PROD with NOTICES
Federal Register / Vol. 79, No. 173 / Monday, September 8, 2014 / Notices 53217 

that adjustments to the proposed 

aggregate production quotas and 

assessment of annual needs for 

alfentanil, cocaine, codeine-N-oxide, 

codeine (for sale), dihydrocodeine, 

fentanyl, hydromorphone, levorphanol, 

marihuana, oripavine, oxymorphone 

(for conversion), and ephedrine (for 

sale) are warranted. This notice reflects 

those adjustments. 

Regarding 1-(1,3-Benzodioxol-5-yl)-2- 

(methylamino)butan-1-one (butylone), 

1-(1,3-Benzodioxol-5-yl)-2- 

(methylamino)pentan-1-one (pentylone), 

2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2- 

methoxybenzyl)ethanamine (25BNBOMe), 2-(4-Chloro-2,5- 

dimethoxyphenyl)-N-(2- 

methoxybenzyl)ethanamine (25CNBOMe), 2-(4-Iodo-2,5- 

dimethoxyphenyl)-N-(2- 

methoxybenzyl)ethanamine (25INBOMe), 2-(Methylamino)-1- 

phenylpentan-1-one (pentedrone), 3- 

Fluoro-N-methylcathinone (3-FMC), 4- 

Fluoro-N-methylcathinone (4-FMC), 4- 

Anilino-N-phenethyl-4-piperidine 

(ANPP), 4-Methyl-N-ethylcathinone (4- 

MEC), 4-Methyl-apyrrolidinopropiophenone (4-MePPP), 

alpha-Pyrrolidinobutiophenone (aPBP), alpha-Pyrrolidinopentiophenone 

(a-PVP), amphetamine (for sale), 

dihydrocodeine, fentanyl, 

hydromorphone, levorphanol, 

marihuana, N-(1-Amino-3,3-dimethyl-1- 

oxobutan-2-yl)-1-pentyl-1H-indazole-3- 

carboxamide (ADB-PINACA), N-(1- 

Amino-3-methyl-1-oxobutan-2-yl)-1-(4- 

fluorobenzyl)-1H-indazole-3- 

carboxamide (AB-FUBINACA), 

naphthylpyrovalerone (naphyrone), 

oxycodone (for conversion), 

oxymorphone (for sale), Quinolin-8-yl 1- 

(5-fluoropentyl)-1H-indole-3- 

carboxylate (5-Flouro-PB-22), and 

Quinolin-8-yl 1-pentyl-1H-indole-3- 

carboxylate (PB-22), the DEA has 

determined that the proposed aggregate 

production quotas are sufficient to 

provide for the 2015 estimated medical, 

scientific, research, and industrial needs 

of the United States, export 

requirements, and the establishment 

and maintenance of reserve stocks. This 

notice finalizes these aggregate 

production quotas at the same amounts 

as proposed. 

As described in the previously 

published notice proposing the 2015 

aggregate production quotas and 

assessment of annual needs, the DEA 

has specifically considered that 

inventory allowances granted to 

individual manufacturers may not 

always result in the availability of 

sufficient quantities to maintain an 

adequate reserve stock pursuant to 21 

U.S.C. 826(a), as intended. See 21 CFR 

1303.24. This would be concerning if a 

natural disaster or other unforeseen 

event resulted in substantial disruption 

to the amount of controlled substances 

available to provide for legitimate 

public need. As such, the DEA has 

included in all established schedule II 

aggregate production quotas, and certain 

schedule I aggregate production quotas, 

an additional 25% of the estimated 

medical, scientific, and research needs 

as part of the amount necessary to 

ensure the establishment and 

maintenance of reserve stocks. The 

resulting established aggregate 

production quota will reflect these 

included amounts. This action will not 

affect the ability of manufacturers to 

maintain inventory allowances as 

specified by regulation. The DEA 

expects that maintaining this reserve in 

certain established aggregate production 

quotas will mitigate adverse public 

effects if an unforeseen event results in 

the substantial disruption to the amount 

of controlled substances available to 

provide for legitimate public need, as 

determined by the DEA. The DEA does 

not anticipate utilizing the reserve in 

the absence of these circumstances. 

In accordance with 21 U.S.C. 826, 21 

CFR 1303.11, and 21 CFR 1315.11, the 

Deputy Administrator hereby 

establishes the 2015 aggregate 

production quotas for the following 

schedule I and II controlled substances 

and the 2015 assessment of annual 

needs for the list I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine, expressed in 

grams of anhydrous acid or base, as 

follows: 

Basic class Established 

2015 quotas (g) 

Schedule I 

(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144) ........................................................................... 15 

[1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (XLR11) ............................................................. 15 

1-(1,3-Benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone) ............................................................................................... 15 

1-(1,3-Benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone) ........................................................................................... 15 

1-(1-Phenylcyclohexyl)pyrrolidine ................................................................................................................................................ 10 

1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) .................................................................................................................... 45 

1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) ................................................................................................................... 45 

1-[1-(2-Thienyl)cyclohexyl]piperidine ........................................................................................................................................... 15 

1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200) ....................................................................................................... 45 

1-Butyl-3-(1-naphthoyl)indole (JWH-073) .................................................................................................................................... 45 

1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-18 and RCS-8) ................................................................................... 45 

1-Hexyl-3-(1-naphthoyl)indole (JWH-019) ................................................................................................................................... 45 

1-Methyl-4-phenyl-4-propionoxypiperidine ................................................................................................................................... 2 

1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678) .............................................................................................................. 45 

1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203) .................................................................................................................... 45 

1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250) ................................................................................................................ 45 

1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398) .................................................................................................................... 45 

1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122) ................................................................................................................... 45 

1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19, RCS-4) ............................................................................................................ 45 

1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081) ............................................................................................................... 45 

2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C-P) .............................................................................................................. 30 

2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E) ................................................................................................................... 30 

2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D) ................................................................................................................ 30 

2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N) .................................................................................................................. 30 

2-(2,5-Dimethoxyphenyl)ethanamine (2C-H) ............................................................................................................................... 30 

2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36) ................ 15 

2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C) ................................................................................................................ 30 

2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82) ................ 15 

2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I) ...................................................................................................................... 30 


rmajette on DSK2TPTVN1PROD with NOTICES
53218 Federal Register / Vol. 79, No. 173 / Monday, September 8, 2014 / Notices 

Basic class Established 

2015 quotas (g) 

2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5) .......................... 15 

2-(Methylamino)-1-phenylpentan-1-one (pentedrone) ................................................................................................................. 15 

2,5-Dimethoxy-4-ethylamphetamine (DOET) .............................................................................................................................. 25 

2,5-Dimethoxy-4-n-propylthiophenethylamine ............................................................................................................................. 25 

2,5-Dimethoxyamphetamine ........................................................................................................................................................ 25 

2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2) ........................................................................................................ 30 

2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4) .................................................................................................. 30 

3,4,5-Trimethoxyamphetamine .................................................................................................................................................... 25 

3,4-Methylenedioxyamphetamine (MDA) .................................................................................................................................... 55 

3,4-Methylenedioxymethamphetamine (MDMA) ......................................................................................................................... 50 

3,4-Methylenedioxy-N-ethylamphetamine (MDEA) ..................................................................................................................... 40 

3,4-Methylenedioxy-N-methylcathinone (methylone) .................................................................................................................. 50 

3,4-Methylenedioxypyrovalerone (MDPV) ................................................................................................................................... 35 

3-Fluoro-N-methylcathinone (3-FMC) .......................................................................................................................................... 15 

3-Methylfentanyl ........................................................................................................................................................................... 2 

3-Methylthiofentanyl ..................................................................................................................................................................... 2 

4-Bromo-2,5-dimethoxyamphetamine (DOB) .............................................................................................................................. 25 

4-Bromo-2,5-dimethoxyphenethylamine (2-CB) .......................................................................................................................... 25 

4-Fluoro-N-methylcathinone (4-FMC) .......................................................................................................................................... 15 

4-Methoxyamphetamine .............................................................................................................................................................. 100 

4-Methyl-2,5-dimethoxyamphetamine (DOM) .............................................................................................................................. 25 

4-Methylaminorex ........................................................................................................................................................................ 25 

4-Methyl-N-ethylcathinone (4-MEC) ............................................................................................................................................ 15 

4-Methyl-N-methylcathinone (mephedrone) ................................................................................................................................ 45 

4-Methyl-a-pyrrolidinopropiophenone (4-MePPP) ....................................................................................................................... 15 

5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol ................................................................................................. 68 

5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8-homolog) ................... 53 

5-Methoxy-3,4-methylenedioxyamphetamine .............................................................................................................................. 25 

5-Methoxy-N,N-diisopropyltryptamine .......................................................................................................................................... 25 

5-Methoxy-N,N-dimethyltryptamine ............................................................................................................................................. 25 

Acetyl-alpha-methylfentanyl ......................................................................................................................................................... 2 

Acetyldihydrocodeine ................................................................................................................................................................... 2 

Acetylmethadol ............................................................................................................................................................................ 2 

Allylprodine .................................................................................................................................................................................. 2 

Alphacetylmethadol ...................................................................................................................................................................... 2 

alpha-Ethyltryptamine .................................................................................................................................................................. 25 

Alphameprodine ........................................................................................................................................................................... 2 

Alphamethadol ............................................................................................................................................................................. 2 

alpha-Methylfentanyl .................................................................................................................................................................... 2 

alpha-Methylthiofentanyl .............................................................................................................................................................. 2 

alpha-Methyltryptamine (AMT) .................................................................................................................................................... 25 

alpha-Pyrrolidinobutiophenone (a-PBP) ...................................................................................................................................... 15 

alpha-Pyrrolidinopentiophenone (a-PVP) .................................................................................................................................... 15 

Aminorex ...................................................................................................................................................................................... 25 

Benzylmorphine ........................................................................................................................................................................... 2 

Betacetylmethadol ....................................................................................................................................................................... 2 

beta-Hydroxy-3-methylfentanyl .................................................................................................................................................... 2 

beta-Hydroxyfentanyl ................................................................................................................................................................... 2 

Betameprodine ............................................................................................................................................................................. 2 

Betamethadol ............................................................................................................................................................................... 4 

Betaprodine .................................................................................................................................................................................. 2 

Bufotenine .................................................................................................................................................................................... 3 

Cathinone ..................................................................................................................................................................................... 70 

Codeine methylbromide ............................................................................................................................................................... 5 

Codeine-N-oxide .......................................................................................................................................................................... 305 

Desomorphine .............................................................................................................................................................................. 5 

Diethyltryptamine ......................................................................................................................................................................... 25 

Difenoxin ...................................................................................................................................................................................... 50 

Dihydromorphine .......................................................................................................................................................................... 3,990,000 

Dimethyltryptamine ...................................................................................................................................................................... 35 

Dipipanone ................................................................................................................................................................................... 5 

Fenethylline .................................................................................................................................................................................. 5 

gamma-Hydroxybutyric acid ........................................................................................................................................................ 70,250,000 

Heroin .......................................................................................................................................................................................... 25 

Hydromorphinol ............................................................................................................................................................................ 2 

Hydroxypethidine ......................................................................................................................................................................... 2 

Ibogaine ....................................................................................................................................................................................... 5 

Lysergic acid diethylamide (LSD) ................................................................................................................................................ 35 

Marihuana .................................................................................................................................................................................... 125,000 

Mescaline ..................................................................................................................................................................................... 25 

Methaqualone .............................................................................................................................................................................. 10 

Methcathinone ............................................................................................................................................................................. 25 

Methyldesorphine ......................................................................................................................................................................... 5 


rmajette on DSK2TPTVN1PROD with NOTICES
Federal Register / Vol. 79, No. 173 / Monday, September 8, 2014 / Notices 53219 

Basic class Established 

2015 quotas (g) 

Methyldihydromorphine ................................................................................................................................................................ 2 

Morphine methylbromide ............................................................................................................................................................. 5 

Morphine methylsulfonate ............................................................................................................................................................ 5 

Morphine-N-oxide ........................................................................................................................................................................ 350 

N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide (AKB48) ................................................................................................ 15 

N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (ADB-PINACA) ............................................. 15 

N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) .................................. 15 

N,N-Dimethylamphetamine .......................................................................................................................................................... 25 

Naphthylpyrovalerone (naphyrone) ............................................................................................................................................. 15 

N-Benzylpiperazine ...................................................................................................................................................................... 25 

N-Ethyl-1-phenylcyclohexylamine ................................................................................................................................................ 5 

N-Ethylamphetamine ................................................................................................................................................................... 24 

N-Hydroxy-3,4-methylenedioxyamphetamine .............................................................................................................................. 24 

Noracymethadol ........................................................................................................................................................................... 2 

Norlevorphanol ............................................................................................................................................................................. 52 

Normethadone ............................................................................................................................................................................. 2 

Normorphine ................................................................................................................................................................................ 18 

Phenomorphan ............................................................................................................................................................................ 2 

Psilocybin ..................................................................................................................................................................................... 30 

Psilocyn ........................................................................................................................................................................................ 30 

Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5-fluoro-PB-22; 5F-PB-22) ................................................................ 15 

Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22; QUPIC) ................................................................................................ 15 

Tetrahydrocannabinols ................................................................................................................................................................ 497,500 

Thiofentanyl ................................................................................................................................................................................. 2 

Tilidine .......................................................................................................................................................................................... 10 

Trimeperidine ............................................................................................................................................................................... 2 

Schedule II 

1-Phenylcyclohexylamine ............................................................................................................................................................ 5 

1-Piperidinocyclohexanecarbonitrile ............................................................................................................................................ 5 

4-Anilino-N-phenethyl-4-piperidine (ANPP) ................................................................................................................................. 2,687,500 

Alfentanil ...................................................................................................................................................................................... 17,750 

Alphaprodine ................................................................................................................................................................................ 3 

Amobarbital .................................................................................................................................................................................. 25,125 

Amphetamine (for conversion) .................................................................................................................................................... 21,875,000 

Amphetamine (for sale) ............................................................................................................................................................... 37,500,000 

Carfentanil .................................................................................................................................................................................... 19 

Cocaine ........................................................................................................................................................................................ 275,000 

Codeine (for conversion) ............................................................................................................................................................. 50,000,000 

Codeine (for sale) ........................................................................................................................................................................ 49,500,000 

Dextropropoxyphene .................................................................................................................................................................... 19 

Dihydrocodeine ............................................................................................................................................................................ 226,375 

Diphenoxylate .............................................................................................................................................................................. 1,337,500 

Ecgonine ...................................................................................................................................................................................... 174,375 

Ethylmorphine .............................................................................................................................................................................. 3 

Fentanyl ....................................................................................................................................................................................... 2,150,000 

Glutethimide ................................................................................................................................................................................. 3 

Hydrocodone (for conversion) ..................................................................................................................................................... 137,500 

Hydrocodone (for sale) ................................................................................................................................................................ 99,625,000 

Hydromorphone ........................................................................................................................................................................... 7,000,000 

Isomethadone .............................................................................................................................................................................. 5 

Levo-alphacetylmethadol (LAAM) ................................................................................................................................................ 4 

Levomethorphan .......................................................................................................................................................................... 5 

Levorphanol ................................................................................................................................................................................. 7,125 

Lisdexamfetamine ........................................................................................................................................................................ 29,750,000 

Meperidine ................................................................................................................................................................................... 6,250,000 

Meperidine Intermediate-A .......................................................................................................................................................... 6 

Meperidine Intermediate-B .......................................................................................................................................................... 11 

Meperidine Intermediate-C .......................................................................................................................................................... 6 

Metazocine ................................................................................................................................................................................... 19 

Methadone (for sale) ................................................................................................................................................................... 31,875,000 

Methadone Intermediate .............................................................................................................................................................. 34,375,000 

Methamphetamine ....................................................................................................................................................................... 2,061,375 

[1,250,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 750,000 grams for methamphetamine mostly 

for conversion to a schedule III product; and 61,375 grams for methamphetamine (for sale)] 

Methylphenidate ........................................................................................................................................................................... 83,750,000 

Morphine (for conversion) ............................................................................................................................................................ 91,250,000 

Morphine (for sale) ...................................................................................................................................................................... 62,500,000 

Nabilone ....................................................................................................................................................................................... 18,750 

Noroxymorphone (for conversion) ............................................................................................................................................... 17,500,000 


rmajette on DSK2TPTVN1PROD with NOTICES
53220 Federal Register / Vol. 79, No. 173 / Monday, September 8, 2014 / Notices 

Basic class Established 

2015 quotas (g) 

Noroxymorphone (for sale) .......................................................................................................................................................... 1,475,000 

Opium (powder) ........................................................................................................................................................................... 112,500 

Opium (tincture) ........................................................................................................................................................................... 687,500 

Oripavine ...................................................................................................................................................................................... 35,000,000 

Oxycodone (for conversion) ........................................................................................................................................................ 8,350,000 

Oxycodone (for sale) ................................................................................................................................................................... 137,500,000 

Oxymorphone (for conversion) .................................................................................................................................................... 29,000,000 

Oxymorphone (for sale) ............................................................................................................................................................... 7,750,000 

Pentobarbital ................................................................................................................................................................................ 35,000,000 

Phenazocine ................................................................................................................................................................................ 6 

Phencyclidine ............................................................................................................................................................................... 19 

Phenmetrazine ............................................................................................................................................................................. 3 

Phenylacetone ............................................................................................................................................................................. 9,375,000 

Racemethorphan ......................................................................................................................................................................... 3 

Remifentanil ................................................................................................................................................................................. 3,750 

Secobarbital ................................................................................................................................................................................. 215,003 

Sufentanil ..................................................................................................................................................................................... 6,255 

Tapentadol ................................................................................................................................................................................... 12,500,000 

Thebaine ...................................................................................................................................................................................... 125,000,000 

List I Chemicals 

Ephedrine (for conversion) .......................................................................................................................................................... 1,000,000 

Ephedrine (for sale) ..................................................................................................................................................................... 4,000,000 

Phenylpropanolamine (for conversion) ........................................................................................................................................ 44,800,000 

Phenylpropanolamine (for sale) ................................................................................................................................................... 8,500,000 

Pseudoephedrine (for conversion) .............................................................................................................................................. 7,000 

Pseudoephedrine (for sale) ......................................................................................................................................................... 224,500,000 

The Deputy Administrator also 

establishes aggregate production quotas 

for all other schedule I and II controlled 

substances included in 21 CFR 1308.11 

and 1308.12 at zero. In accordance with 

21 CFR 1303.13 and 21 CFR 1315.13, 

upon consideration of the relevant 

factors, the Deputy Administrator may 

adjust the 2015 aggregate production 

quotas and assessment of annual needs 

as needed. 

Dated: September 2, 2014. 

Thomas M. Harrigan, 

Deputy Administrator. 

[FR Doc. 2014–21280 Filed 9–5–14; 8:45 am] 

BILLING CODE 4410–09–P 

OFFICE OF SCIENCE AND 

TECHNOLOGY POLICY 

National Nanotechnology Coordination 

Office 

Nanoscale Science, Engineering, and 

Technology Subcommittee; Committee 

on Technology, National Science and 

Technology Council; Meeting 

ACTION: Notice of public meeting. 

SUMMARY: The National Nanotechnology 

Coordination Office (NNCO), on behalf 

of the Nanoscale Science, Engineering, 

and Technology (NSET) Subcommittee 

of the Committee on Technology, 

National Science and Technology 

Council (NSTC), will hold a technical 

interchange meeting entitled ‘‘Realizing 

the Promise of Carbon Nanotubes— 

Challenges, Opportunities and the 

Pathway to Commercialization’’ on 

September 15, 2014. The meeting will 

be sponsored by the National 

Nanotechnology Initiative (NNI) and cosponsored by the National Aeronautics 

and Space Administration (NASA). The 

objectives of this meeting are to identify, 

discuss, and report the technical 

barriers preventing the production of 

carbon nanotube-based materials with 

electrical and mechanical properties 

approaching theoretical values, and to 

explore ways to overcome these barriers. 

Obstacles preventing the full 

exploitation of the multifunctional 

nature of carbon nanotube materials will 

also be discussed. This one-day meeting 

will assemble some of the Nation’s 

leading experts in carbon nanotube 

research and development, as well as 

executives and experts from the Federal 

government, academia, and private 

sector. 

DATES: The technical interchange 

meeting will be held Monday, 

September 15, 2014 from 8:00 a.m. until 

5:15 p.m. 

ADDRESSES: The technical interchange 

meeting will be held at the National 

Aeronautics and Space Administration 

(NASA) Headquarters, 300 E Street 

Southwest, Washington, DC 20546. 

FOR FURTHER INFORMATION, CONTACT: Dr. 

Tarek Fadel, 703–292–7926, tfadel@

nnco.nano.gov, NNCO. Additional 

information is posted at: http://

nano.gov/2014CNTTechInterchange. 

Registration: Registration opens on 

September 8, 2014. Due to space 

limitations, pre-registration for the 

technical interchange meeting is 

required. Written notices of 

participation by email should be sent to 

dpetreski@nnco.nano.gov or mailed to 

Diana Petreski, 4201 Wilson Blvd., 

Stafford II, Suite 405, Arlington, VA 

22230. Please provide your full name, 

title, affiliation and email or mailing 

address when registering. Registration is 

on a first-come, first-served basis until 

capacity is reached. Written or 

electronic comments should be 

submitted by email to dpetreski@

nnco.nano.gov until close of business 

September 10, 2014. 

Meeting Accommodations: 

Individuals requiring special 

accommodation to access this meeting 

should contact Diana Petreski at 703– 

292–7922 at least five business days 

prior to the meeting so that appropriate 

arrangements can be made. 

Ted Wackler, 

Deputy Chief of Staff and Assistant Director. 

[FR Doc. 2014–21201 Filed 9–5–14; 8:45 am] 

BILLING CODE P 


rmajette on DSK2TPTVN1PROD with NOTICES